SYRE · Spyre Therapeutics, Inc.
$88.71
+2.05% last session
End-of-day data · close of 2026-09-10
Market cap
$8B
Enterprise value
$7B
Trailing P/E
—
Forward P/E
-25.2
Dividend yield
—
Beta
3.00
Avg volume
1M
Employees
0K
Daily Change %
2.05%
5 Days Change
-2.30%
10 Days Change
-2.69%
30 Days Change
-15.39%
60 Days Change
-11.06%
Month to Day Change
-1.77%
Year to Day Change
165.35%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SYRE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
Deutsche Bank
Buy$127
+43.2% vs priceWells Fargo
Overweight$115
+29.6% vs priceCitigroup
Buy$97.00
+9.3% vs priceJefferies
Buy$85.00
-4.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Wedbush | Reiterates | Outperform | $123 |
| 2026-09-08 | BTIG | Reiterates | Buy | $121 |
| 2026-08-26 | Deutsche Bank | Maintains | Buy | $135 → $127 |
| 2026-08-26 | Wedbush | Maintains | Outperform | $130 → $123 |
| 2026-08-26 | BTIG | Maintains | Buy | $132 → $121 |
| 2026-08-11 | BTIG | Maintains | Buy | $112 → $132 |
| 2026-08-05 | Wells Fargo | Maintains | Overweight | $90.00 → $115 |
| 2026-08-05 | Guggenheim | Maintains | Buy | $115 → $130 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-10
- RSI (14): RSI is 39 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.5% below the 50-day MA ($98.07).
- Price vs 200-day MA: Trading 40.9% above the 200-day MA ($62.96).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.24) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($14.82) and high ($108.92).
SYRE Price Chart
Loading chart for SYRE…
Fundamentals
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.